News + Font Resize -

IntelliCell seeks patent for new mechanical method to separate SVF from blood vessels in adipose tissue
New York | Thursday, August 23, 2012, 16:00 Hrs  [IST]

IntelliCell BioSciences, Inc., a pioneering regenerative medicine company, has filed a patent application for a new mechanical method to separate stromal vascular fraction (SVF) from the blood vessels in adipose tissue (fat) to be used clinically in regenerative medicine.

The provisional patent, titled, "Isolation of stromal vascular fraction from the blood vessels in adipose tissue using homonogenation, a mechanical method" expands the patent portfolios of IntelliCell in mechanical methods to isolate/separate SVF from blood vessels in adipose tissue.

According to IntelliCell's chairman/CEO Steven Victor MD, "This will strengthen our position in new and different methods of separation of SVF from the blood vessels in adipose tissue. We feel that using a mechanical means of separation of SVF is superior to that by using enzymes since the time and cost are vastly reduced and you do not have to worry about endotoxins in the specimen. I also believe by using mechanical methods of separation we fall within the 'minimally manipulated' guidelines of the FDA CFR 1271.10."

Sarah Young, director of Quality Assurance stated, "This is another exciting discovery in that we have been able to take a technology and develop a protocol to separate SVF so we can have viable cells. This is a significant advancement in the mechanical method of cell separation."

IntelliCell recognizes the future of cellular medicine in SVF therapy. These are vascular cells residing in the walls of all blood vessels in the body and the IntelliCell process will soon harvest these cells from non-living adipose tissue. In the future as part of this homologous process.

Dr Victor said, "The future of medicine has reached an exciting stage with the knowledge that SVF can be used clinically to treat patients for a number of disease states with high unmet clinical needs."

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue.

Post Your Comment

 

Enquiry Form